

## CYP2D6: clonidine

## 2530/2531/2532

IM = intermediate metaboliser (gene dose 0.25-1) (reduced CYP2D6 enzyme activity), NM = normal metaboliser (gene dose 1.25-2.5) (normal CYP2D6 enzyme activity), PM = poor metaboliser (gene dose 0) (absent CYP2D6 enzyme activity), UM = ultra-rapid metaboliser (gene dose ≥ 2.75) (elevated CYP2D6 enzyme activity)

| Source     | Code | Effect | Comments |
|------------|------|--------|----------|
|            |      |        |          |
|            |      |        |          |
| 1          |      |        | ·        |
|            |      |        |          |
| Risk group |      |        |          |

## **Comments:**

- No literature found (PubMed).

Date of literature search: 10 December 2021.

|                        | Phenotype | Code | Gene-drug interaction | Action | Date            |
|------------------------|-----------|------|-----------------------|--------|-----------------|
| KNMP Pharmacogenetics  | PM        |      | no                    | no     | 31 January 2021 |
| Working Group decision | IM        |      | no                    | no     |                 |
|                        | UM        |      | no                    | no     |                 |

## Mechanism:

Clonidine is excreted for 70% via urine (primarily in unchanged form: 40-60% of the dose) and for 20% via faeces. It is not known which enzyme is responsible for the formation of the most important metabolite p-hydroxyclonidine.